Despite the fact that lung cancer remains the most common cause of cancer deaths in Poland, we can talk about a real breakthrough that has been made in recent years. Thanks to immunotherapy, molecularly targeted drugs and precise diagnostics, lung cancer is becoming a chronic disease.
The majority of patients (60-80 percent) at the time of diagnosis are in the advanced (inoperable) stage. Thanks to the revolution in diagnostic methods, the prognosis of patients has improved significantly. More than a dozen drugs are currently registered for the treatment of NDRP. This applies to patients diagnosed with certain genetic changes.
The type of mutation matters
One of the best-studied molecular abnormalities in lung cancer is a mutation in the EGFR gene. This mutation affects about 7-10 percent. Modern targeted drugs (triton kinase inhibitors) have improved the prognosis of pa...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
